Logos Global Management LP Q4 2020 Filing
Filed February 16, 2021
Portfolio Value
$1.2T
Holdings
59
Report Date
Q4 2020
Filing Type
13F-HR
All Holdings (59 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | ALXOALX ONCOLOGY HLDGS INC | 3,156,981 | $272.1B | 23.33% | |
| 2 | OLMAOLEMA PHARMACEUTICALS INC | 3,743,875 | $180.0B | 15.43% | |
| 3 | NKTXNKARTA INC | 1,682,178 | $103.4B | 8.86% | |
| 4 | —FORMA THERAPEUTICS HLDGS INC | 1,400,000 | $48.9B | 4.19% | |
| 5 | TGTXTG THERAPEUTICS INC | 850,000 | $44.2B | 3.79% | |
| 6 | DYNDYNE THERAPEUTICS INC | 1,604,392 | $33.7B | 2.89% | |
| 7 | —ATHIRA PHARMA INC | 947,873 | $32.5B | 2.78% | |
| 8 | KROSKEROS THERAPEUTICS INC | 450,000 | $31.7B | 2.72% | |
| 9 | RPTXREPARE THERAPEUTICS INC | 676,894 | $23.2B | 1.99% | |
| 10 | —KINNATE BIOPHARMA INC | 569,602 | $22.7B | 1.94% | |
| 11 | COGTCOGENT BIOSCIENCES INC | 1,920,500 | $21.6B | 1.85% | |
| 12 | BTAIEURBIOXCEL THERAPEUTICS INC | 430,000 | $19.9B | 1.70% | |
| 13 | APLSAPELLIS PHARMACEUTICALS INC | 300,000 | $17.2B | 1.47% | |
| 14 | —BIOHAVEN PHARMACTL HLDG CO L | 200,000 | $17.1B | 1.47% | Call |
| 15 | RNAAVIDITY BIOSCIENCES INC | 671,454 | $17.1B | 1.47% | |
| 16 | ALGSALIGOS THERAPEUTICS INC | 606,548 | $16.8B | 1.44% | |
| 17 | CCCCC4 THERAPEUTICS INC | 477,928 | $15.8B | 1.36% | |
| 18 | LRMRLARIMAR THERAPEUTICS INC | 715,000 | $15.3B | 1.31% | |
| 19 | CMPSCOMPASS PATHWAYS PLC | 300,000 | $14.3B | 1.23% | |
| 20 | SPRYSILVERBACK THERAPEUTICS INC | 300,000 | $13.9B | 1.19% | |
| 21 | 1K0IGM BIOSCIENCES INC | 150,000 | $13.2B | 1.14% | |
| 22 | KRTXKARUNA THERAPEUTICS INC | 120,000 | $12.2B | 1.05% | |
| 23 | ABCLABCELLERA BIOLOGICS INC | 300,000 | $12.1B | 1.03% | |
| 24 | MRTXEURMIRATI THERAPEUTICS INC | 50,000 | $11.0B | 0.94% | |
| 25 | —CALLIDITAS THERAPEUTICS AB | 300,000 | $10.1B | 0.86% | |
| 26 | —CURIS INC | 1,200,000 | $9.8B | 0.84% | |
| 27 | KALVKALVISTA PHARMACEUTICALS INC | 490,000 | $9.3B | 0.80% | |
| 28 | —MIRAGEN THERAPEUTICS INC | 550,000 | $9.0B | 0.78% | |
| 29 | PASGPASSAGE BIO INC | 344,438 | $8.8B | 0.75% | |
| 30 | —VINCERA PHARMA INC | 400,000 | $7.7B | 0.66% | |
| 31 | NRIXNURIX THERAPEUTICS INC | 230,297 | $7.6B | 0.65% | |
| 32 | —THERAPEUTICS ACQUISITION COR | 500,000 | $7.0B | 0.60% | |
| 33 | KYMRKYMERA THERAPEUTICS INC | 110,920 | $6.9B | 0.59% | |
| 34 | EPIEURESSA PHARMA INC | 550,000 | $6.6B | 0.56% | |
| 35 | STTKSHATTUCK LABS INC | 121,562 | $6.4B | 0.55% | |
| 36 | PMVPPMV PHARMACEUTICALS INC | 100,000 | $6.2B | 0.53% | |
| 37 | LUNGPULMONX CORP | 75,000 | $5.2B | 0.44% | |
| 38 | EYPTEYEPOINT PHARMACEUTICALS INC | 699,999 | $4.6B | 0.39% | |
| 39 | ANNXANNEXON INC | 159,622 | $4.0B | 0.34% | |
| 40 | BDTXBLACK DIAMOND THERAPEUTICS I | 123,465 | $4.0B | 0.34% | |
| 41 | —HEALTH SCIENCES ACQ CORP 2 | 300,000 | $3.8B | 0.33% | |
| 42 | PCVXVAXCYTE INC | 140,000 | $3.7B | 0.32% | |
| 43 | HRMYHARMONY BIOSCIENCES HLDGS IN | 100,000 | $3.6B | 0.31% | |
| 44 | BMY-RBRISTOL-MYERS SQUIBB CO | 5,050,000 | $3.5B | 0.30% | |
| 45 | —NOVUS THERAPEUTICS INC | 224,071 | $3.5B | 0.30% | |
| 46 | 5E7ITEOS THERAPEUTICS INC | 100,000 | $3.4B | 0.29% | |
| 47 | OMGBPOUTSET MED INC | 50,000 | $2.8B | 0.24% | |
| 48 | —PANACEA ACQUISITION CORP | 200,000 | $2.6B | 0.22% | |
| 49 | —BCTG ACQUISITION CORP | 200,000 | $2.3B | 0.20% | |
| 50 | MLTXHELIX ACQUISITION CORP | 200,000 | $2.3B | 0.19% | |
| 51 | —EARGO INC | 50,000 | $2.2B | 0.19% | |
| 52 | OPTEYOPTHEA LTD | 160,000 | $1.8B | 0.15% | |
| 53 | PLRXPLIANT THERAPEUTICS INC | 76,426 | $1.7B | 0.15% | |
| 54 | TVTXTRAVERE THERAPEUTICS INC | 61,152 | $1.7B | 0.14% | |
| 55 | CERE1EURCEREVEL THERAPEUTICS HLDNG I | 100,000 | $1.7B | 0.14% | |
| 56 | —APPLIED MOLECULAR TRANS INC | 42,847 | $1.3B | 0.11% | |
| 57 | —FS DEV CORP | 100,000 | $1.1B | 0.09% | |
| 58 | GBIOGBXGENERATION BIO CO | 17,000 | $482.0M | 0.04% | |
| 59 | —CEREVEL THERAPEUTICS HLDNG I | 33,333 | $188.0M | 0.02% |